Infliximab-induced discoid lupus erythematosus

被引：19

作者：

Cemil, B. C. ^{[1
]}

Atas, H. ^{[1
]}

Canpolat, F. ^{[1
]}

Akca, Y. ^{[2
]}

Sasmaz, R. ^{[1
]}

机构：

[1] Diskapi Yildirim Beyazit Educ & Res Hosp, Dept Dermatol, Minist Hlth, Ankara, Turkey

[2] Diskapi Yildirim Beyazit Educ & Res Hosp, Dept Pathol, Minist Hlth, Ankara, Turkey

来源：

LUPUS | 2013年 / 22卷 / 05期

关键词：

Anti-tumor necrosis factor therapies; lupus syndrome; rheumatoid arthritis; NECROSIS-FACTOR-ALPHA; RHEUMATOID-ARTHRITIS; ETANERCEPT; THERAPY; APOPTOSIS;

D O I：

10.1177/0961203313479423

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Anti-tumor necrosis factor-alpha (TNF-alpha) immunotherapy is currently used in the treatment of various inflammatory diseases such as rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. Infliximab is a chimeric monoclonal antibody that binds to transmembrane-bound and soluble TNF-alpha. Previously, a discoid lupus erythematosus-like eruption linked to its use was rarely reported in patients with rheumatoid arthritis. We present a case of rheumatoid arthritis which developed such an eruption after treatment with infliximab. The lesions resolved after the discontinuation of infliximab. In the present case, the clinical, serological and immunohistochemical features of our patient are discussed with the literature. Lupus (2013) 22, 515-518.

引用

页码：515 / 518

页数：4

共 19 条

[1]

The role of tumor necrosis factor-alpha in systemic lupus erythematosus [J].

Aringer, Martin ;

Smolen, Josef S. .

ARTHRITIS RESEARCH & THERAPY, 2008, 10 (01)

[2]

Autoimmune skin rashes associated with etanercept for rheumatoid arthritis [J].

Brion, PH ;

Mittal-Henkle, A ;

Kalunian, KC .

ANNALS OF INTERNAL MEDICINE, 1999, 131 (08) :634-634

[3]

Anti-TNF-α-induced systemic lupus syndrome [J].

Debandt, M ;

Vittecoq, O ;

Descamps, V ;

Le Loët, X ;

Meyer, O .

CLINICAL RHEUMATOLOGY, 2003, 22 (01) :56-61

[4]

Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα [J].

Eriksson, C ;

Engstrand, S ;

Sundqvist, KG ;

Rantapää-Dahlqvist, S .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (03) :403-407

[5]

Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors [J].

Exarchou, S. A. ;

Voulgari, P. V. ;

Markatseli, T. E. ;

Zioga, A. ;

Drosos, A. A. .

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2009, 38 (05) :328-331

[6]

Drug-induced lupus following treatment with infliximab in rheumatoid arthritis [J].

Favalli, E ;

Sinigaglia, L ;

Varenna, M ;

Arnoldi, C .

LUPUS, 2002, 11 (11) :753-755

[7]

Gonnet-Gracia C, 2008, CLIN EXP RHEUMATOL, V26, P401

[8]

A review of the use of infliximab to manage cutaneous dermatoses [J].

Gupta, AK ;

Skinner, AR .

JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2004, 8 (02) :77-89

[9]

Role of apoptosis in autoimmunity [J].

Lorenz, HM ;

Herrmann, M ;

Winkler, T ;

Gaipl, U ;

Kalden, JR .

APOPTOSIS, 2000, 5 (05) :443-449

[10]

Dermatological complications of etanercept therapy for rheumatoid arthritis [J].

Misery, L ;

Perrot, JL ;

Gentil-Perret, A ;

Pallot-Prades, B ;

Cambazard, F ;

Alexandre, C .

BRITISH JOURNAL OF DERMATOLOGY, 2002, 146 (02) :334-335

← 1 2 →